Macquarie said that the sector is currently at a turning point, driven by increased pharmaceutical outsourcing due to drug pricing pressures and geopolitical factors, prompting a global restructuring of the pharmaceutical supply chain.
Groww’s Ishan Bansal sees structural shift in derivatives participation post regulatory changes
Derivatives business faces a structural reset post FY25 regulatory changes, with growth now driven by a smaller but stable customer base, increased market volatility, and
April 21, 2026